| Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. | |
| | |
MedLine Citation:
|
PMID: 15452046 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To develop a population model capable of describing the profile of the effect of intravitreal triamcinolone acetonide in the treatment of diabetic diffuse macular edema. METHODS: The results of 51 injections in 37 eyes (33 patients) with diffuse diabetic macular edema were studied, by using population pharmacokinetic-pharmacodynamic modeling, without triamcinolone concentration measurements. This approach was supported by the pharmacokinetic hypothesis that the intravitreal triamcinolone concentration decreases in accordance with an exponential biphasic equation. Central macular thickness (CMT), measured by optical coherence tomography was chosen as the pharmacodynamic parameter. RESULTS: The pharmacodynamic profile of the effect of triamcinolone on CMT was characterized by a curve in three phases: a fast decrease, a steady state, and a relapse. The confidence interval of most of the estimated parameters of the model was narrow. The mean estimated half-life of triamcinolone +/- SD was 15.4 +/- 1.9 days, and the mean maximum duration of its effect (+/-SD), 140 +/- 17 days. CONCLUSIONS: Pharmacokinetic-pharmacodynamic modeling using CMT constitutes a valid alternative to pharmacokinetic studies. This approach worked excellently in the present study, and the results are consistent with those published for the intraocular pharmacokinetics of triamcinolone acetonide in the human eye. The authors conclude that this type of investigation is of interest, as it avoids intraocular measurements as far as possible. |
| | |
Authors:
|
François Audren; Michel Tod; Pascale Massin; Rym Benosman; Belkacem Haouchine; Ali Erginay; Charles Caulin; Alain Gaudric; Jean-François Bergmann |
Related Documents
:
|
3580516 - Definition of mean residence times in pharmacokinetics. 17190376 - Population pharmacokinetics of ibandronate in caucasian and japanese healthy males and ... 6977636 - Physiologic model for the pharmacokinetics of 2'deoxycoformycin in normal and leukemic ... 15176076 - Prediction of human pharmacokinetic profile in animal scale up based on normalizing tim... 6610356 - Development of quantitative tools for filter-aided dichromats. 18249736 - Bayesian wavelet networks for nonparametric regression. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Investigative ophthalmology & visual science Volume: 45 ISSN: 0146-0404 ISO Abbreviation: Invest. Ophthalmol. Vis. Sci. Publication Date: 2004 Oct |
Date Detail:
|
Created Date: 2004-09-28 Completed Date: 2004-11-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7703701 Medline TA: Invest Ophthalmol Vis Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 3435-41 Citation Subset: IM |
Affiliation:
|
Ophthalmology Department, Hôpital Lariboisière, Université Paris 7, Paris, France. francoisaudren@hotmail.com <francoisaudren@hotmail.com> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Diabetic Retinopathy / drug therapy*, metabolism Glucocorticoids / pharmacokinetics*, pharmacology* Half-Life Humans Injections Macula Lutea / drug effects*, metabolism, pathology Macular Edema / drug therapy*, metabolism Middle Aged Models, Biological* Time Factors Tomography, Optical Coherence Triamcinolone Acetonide / pharmacokinetics*, pharmacology* Vitreous Body |
| Chemical | |
Reg. No./Substance:
|
0/Glucocorticoids; 76-25-5/Triamcinolone Acetonide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma...
Next Document: The impact of visual impairment on functional vision of children in rural South India: the Kariapatt...